Yüklüyor......
Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia
Ezetimibe is a selective cholesterol absorption inhibitor with an excellent side-effect profile, able to reduce low-density lipoprotein (LDL) cholesterol by 15-25% from baseline in monotherapy and on top of statins and fibrates. Yet, it seems that ezetimibe produces quantitative rather than qualitat...
Kaydedildi:
| Asıl Yazarlar: | , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Termedia Publishing House
2011
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3258692/ https://ncbi.nlm.nih.gov/pubmed/22291726 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/aoms.2011.20597 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|